TECX on Nasdaq

Tectonic Therapeutic, Inc.

American biological products company based in Watertown.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with another stock.

TickerTECX on Nasdaq
IndustryBiological Products, (No Diagnostic Substances)
HeadquartersNY
Incorporated inNY²
Business address490 Arsenal Way, Suite 200, Watertown, Ma²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income³⁴⁵⁶⁷⁸-$84.0M in 2025+11% since 2019

Net income³⁴⁵⁶⁷⁸-$74.2M in 2025+2% since 2019

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁸

Period ending	2025-12-31	2024-12-31
Research and development	$63.5M	$41.4M
General and administrative	$20.5M	$16.7M
Total operating expenses	$84.0M	$58.0M
Loss from operations	-$84.0M	-$58.0M
Interest income	$11.3M	$4.3M
Interest expense	-$63.0K	-$107.0K
Change in fair value of SAFE liabilities	$0	-$3.6M
Other expense	-$119.0K	-$511.0K
Total other income, net	$11.1M	$33.0K
Loss before income tax	-$72.9M	-$58.0M
Income tax expense	-$1.2M	$0
Net loss	-$74.2M	-$58.0M
Foreign currency translation adjustment	-$105.0K	$9.0K
Comprehensive loss	-$74.3M	-$58.0M
Net loss per share, basic	-$4.05	-$6.83
Net loss per share, diluted	-$4.05	-$6.83
Weighted-average common shares outstanding, basic	18.3M shares	8.5M shares
Weighted-average common shares outstanding, diluted	18.3M shares	8.5M shares

Total assets³⁴⁵⁶⁷⁸$261.0M in 2025+30% since 2019

Total liabilities³⁴⁵⁶⁷⁸$9.7M in 2025−33% since 2019

Shareholders’ equity⁴⁵⁶⁷⁸$251.3M in 2025+35% since 2019

Cash³⁴⁵⁶⁷⁸$253.8M in 2025+36% since 2019

Long-term debt⁴⁵$15.0M in 2022+0% since 2021

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.⁸

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$253.8M	$141.2M
Prepaid expenses and other current assets	$3.0M	$5.6M
Restricted cash	$587.0K	$0
Total current assets	$257.4M	$146.9M
Property and equipment, net	$1.2M	$2.2M
Finance right-of-use assets, net	$495.0K	$919.0K
Operating right-of-use assets	$874.0K	$2.2M
Restricted cash	$485.0K	$587.0K
Other assets	$640.0K	$156.0K
Total assets	$261.0M	$152.9M
Accounts payable	$1.1M	$976.0K
Accrued expenses and other current liabilities	$7.3M	$7.8M
Operating lease liability	$889.0K	$2.3M
Finance lease liability	$344.0K	$489.0K
Total current liabilities	$9.7M	$11.6M
Operating lease liability, non-current	$0	$132.0K
Finance lease liability, non-current	$43.0K	$387.0K
Total liabilities	$9.7M	$12.1M
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; no shares issued and outstanding as of December 31, 2025 and December 31, 2024	$0	$0
Common stock, $0.0001 par value; 150,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 18,713,223 and 14,856,309 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	$2.0K	$2.0K
Additional paid-in capital	$474.2M	$289.4M
Accumulated other comprehensive (loss) income	-$96.0K	$9.0K
Accumulated deficit	-$222.7M	-$148.6M
Total stockholders' equity	$251.3M	$140.8M	-$84.6M
Total liabilities and stockholders' equity	$261.0M	$152.9M
Preferred Stock, Shares Authorized	10.0M shares	10.0M shares
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Shares Issued	0 shares	0 shares
Preferred Stock, Shares Outstanding	0 shares	0 shares
Common stock, par value	$0.00	$0.00
Common stock, authorized	150.0M shares	150.0M shares
Common stock, issued	18.7M shares	14.9M shares
Common stock, outstanding	18.7M shares	14.9M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$253.8M	$141.2M
Prepaid expenses and other current assets	$3.0M	$5.6M
Restricted cash	$587.0K	$0
Total current assets	$257.4M	$146.9M
Property and equipment, net	$1.2M	$2.2M
Finance right-of-use assets, net	$495.0K	$919.0K
Operating right-of-use assets	$874.0K	$2.2M
Restricted cash	$485.0K	$587.0K
Other assets	$640.0K	$156.0K
Total assets	$261.0M	$152.9M
Accounts payable	$1.1M	$976.0K
Accrued expenses and other current liabilities	$7.3M	$7.8M
Operating lease liability	$889.0K	$2.3M
Finance lease liability	$344.0K	$489.0K
Total current liabilities	$9.7M	$11.6M
Operating lease liability, non-current	$0	$132.0K
Finance lease liability, non-current	$43.0K	$387.0K
Total liabilities	$9.7M	$12.1M
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; no shares issued and outstanding as of December 31, 2025 and December 31, 2024	$0	$0
Common stock, $0.0001 par value; 150,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 18,713,223 and 14,856,309 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	$2.0K	$2.0K
Additional paid-in capital	$474.2M	$289.4M
Accumulated other comprehensive (loss) income	-$96.0K	$9.0K
Accumulated deficit	-$222.7M	-$148.6M
Total stockholders' equity	$251.3M	$140.8M	-$84.6M
Total liabilities and stockholders' equity	$261.0M	$152.9M
Preferred Stock, Shares Authorized	10.0M shares	10.0M shares
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Shares Issued	0 shares	0 shares
Preferred Stock, Shares Outstanding	0 shares	0 shares
Common stock, par value	$0.00	$0.00
Common stock, authorized	150.0M shares	150.0M shares
Common stock, issued	18.7M shares	14.9M shares
Common stock, outstanding	18.7M shares	14.9M shares

Cash from operations³⁴⁵⁶⁷⁸-$60.1M in 2025−11% since 2019

Capital spending³⁴⁵⁶⁷⁸$208.0K in 2025−87% since 2019

Free cash flow³⁴⁵⁶⁷⁸-$60.3M in 2025−13% since 2019

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁸

Period ending	2025-12-31	2024-12-31
Net loss	-$74.2M	-$58.0M
Depreciation and amortization expense	$1.4M	$1.6M
Stock-based compensation expense	$10.5M	$3.5M
Loss on sale of property and equipment	$153.0K	$0
Reduction in the carrying amount of the operating right-of-use assets	$2.1M	$434.0K
Change in fair value of SAFE liabilities	$0	$3.6M
Prepaid expenses and other current assets	$2.6M	-$3.2M
Other non-current assets	$17.0K	$544.0K
Accounts payable	$116.0K	-$1.4M
Accrued expenses and other current liabilities	-$552.0K	-$5.6M
Operating lease liabilities	-$2.3M	-$565.0K
Net cash used in operating activities	-$60.1M	-$59.1M
Purchase of property and equipment	-$208.0K	-$156.0K
Proceeds from the sale of property and equipment	$70.0K	$0
Net cash used in investing activities	-$138.0K	-$156.0K
Proceeds from the private placement, net of offering costs of $11,928	$173.1M	$0
Proceeds from the Subscription Agreement, net of offering costs of $2,000	$0	$94.6M
Cash acquired in connection with the Merger, net of transaction costs of $7,412	$0	$76.0M
Proceeds from exercise of stock options	$1.2M	$1.6M
Payments for employee taxes related to net share settlement of equity awards	-$17.0K	$0
Payment of deferred offering costs	-$468.0K	$0
Repayment of finance lease obligations	-$489.0K	-$475.0K
Net cash provided by financing activities	$173.4M	$171.7M
Effect of exchange rate changes on cash and cash equivalents	-$95.0K	-$8.0K
Net increase in cash and cash equivalents and restricted cash	$113.0M	$112.5M
Deferred offering costs included in accrued expenses and other liabilities	$35.0K	$0
Right-of-use assets obtained in exchange for new operating lease liabilities	$757.0K	$0
Conversion of SAFEs to Common Stock	$0	$34.1M
Conversion of Convertible Preferred Stock to Common Stock	$0	$80.6M
Transaction Costs	$9.3M

Compare Tectonic Therapeutic, Inc. with another company

Leadership

Who has led Tectonic Therapeutic, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

Chief operating officer

Christian Cortis2024

20202025

Chief executive officerAlise Reicin Jun 24, 2024 to now¹¹
Chief executive officerErik Ostrowski Jul 3, 2023 to Feb 5, 2024¹²
Chief executive officerGeoffrey Mackay Mar 6, 2020 to Feb 10, 2023¹³
PresidentErik Ostrowski Jul 3, 2023 to Feb 5, 2024¹²
PresidentGeoffrey Mackay Mar 6, 2020 to Feb 10, 2023¹³
PresidentBirgitte Volck Dec 19, 2018 to Mar 6, 2020¹⁴
Chief financial officerDaniel Lochner Jun 24, 2024 to now¹⁵
Chief financial officerErik Ostrowski Jan 4, 2019 to Feb 5, 2024¹⁶
Chief financial officerKatina Dorton Jun 20, 2018 to Oct 10, 2018¹⁷
Chief operating officerChristian Cortis Jun 24, 2024 to Jun 24, 2024¹⁸

Board members and other officers (27)

Chief Business OfficerMarc Schwabish Jun 24, 2024 to now¹⁹
Chief Medical OfficerMarcella K. Ruddy Jun 24, 2024 to now²⁰
Chief Scientific OfficerPeter McNamara Jun 24, 2024 to now²¹
Chief Technology OfficerAzadeh Golipour Jun 17, 2022 to Feb 5, 2024²²
Chief Medical OfficerDiana Escolar Jan 22, 2021 to Jun 14, 2021²³
Chief Medical OfficerEssra Ridha Oct 27, 2021 to Feb 5, 2024²⁴
Chief Business OfficerDeanna M. Petersen Mar 6, 2020 to Feb 10, 2023²⁵
OfficerGeoffrey Mackay Jun 20, 2018 to Feb 14, 2020²⁶
Chief Medical OfficerNerissa Kreher Jun 20, 2018 to Oct 10, 2018²⁷
Board memberFrancois Nader Apr 3, 2026 to now²⁸
Board memberJessica Caroline Chutter Jun 10, 2026 to now²⁹
Board memberAlise Reicin Jun 24, 2024 to now¹¹
Board memberPraveen P. Tipirneni Jun 24, 2024 to now³⁰
Board memberStefan Vitorovic Jun 24, 2024 to now³¹
Board memberTerrance McGuire Jun 24, 2024 to now³²
Board memberTimothy A. Springer Jun 24, 2024 to now³³
Board memberGail M. Farfel Oct 21, 2020 to Jun 8, 2023³⁴
Board memberPhilip J. Vickers Jan 9, 2019 to Jun 8, 2023³⁵
Board memberAnnalisa Jenkins Jun 20, 2018 to Jun 8, 2023³⁶
Board memberBruce Booth Jun 20, 2018 to Jun 8, 2023³⁷
Board memberChristopher Paige Jun 20, 2018 to Jun 8, 2023³⁸
Board memberGeoffrey Mackay Jun 20, 2018 to Feb 10, 2023²⁶
Board memberIan T. Clark Jun 20, 2018 to Jun 8, 2023³⁹
Board memberJoshua Resnick Jun 20, 2018 to Jun 20, 2018⁴⁰
Board memberPhilip B. Donenberg Jun 20, 2018 to now⁴¹
Board memberScott Requadt Jun 20, 2018 to Jun 25, 2018⁴²
General counselSteven Avruch Jan 4, 2019 to Feb 5, 2024⁴³

Former names

AvroBio, Inc.Feb 2, 2018 to Jun 18, 2024²

Timeline

Jun 24, 2024New chief executive Alise Reicin becomes CEO¹¹
Jul 3, 2023New chief executive Erik Ostrowski becomes CEO¹²
Mar 6, 2020New chief executive Geoffrey Mackay becomes CEO¹³

Filings

352 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 57 major events, 137 insider forms, 47 large holders, 1 private raises, 90 other. The latest 20:

Oct 2, 20264 EDGAR
Oct 2, 20264 EDGAR
Oct 2, 20264 EDGAR
Oct 2, 20264 EDGAR
Oct 2, 20264 EDGAR
Sep 30, 2026144 EDGAR
Sep 29, 20268-K EDGAR
Sep 8, 20264 EDGAR
Sep 8, 20264 EDGAR
Sep 8, 20264 EDGAR
Sep 8, 20264 EDGAR
Sep 8, 20264 EDGAR
Aug 27, 2026144 EDGAR
Aug 26, 20264 EDGAR
Aug 21, 2026144 EDGAR
Aug 14, 20264 EDGAR
Aug 12, 2026144 EDGAR
Aug 6, 202610-Q EDGAR
Aug 6, 20268-K EDGAR
Jul 1, 20264 EDGAR

The 352 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 47 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

Feb 5, 2025Raised $185 million in a private offering of equity Form D: 29 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Fmr LLC	2,830,378	$97.3M	0.0%	+13,884
TCG Crossover Management, LLC	1,204,891	$41.4M	1.0%	No change
Aberdeen Group plc	1,141,824	$39.3M	0.1%	No change
BlackRock, Inc.	862,592	$29.7M	0.0%	+2,240
First Light Asset Management, LLC	800,726	$27.5M	1.7%	+152,983
Baker Bros. Advisors LP	607,788	$20.9M	0.1%	No change
5AM Venture Management, LLC	606,660	$20.9M	7.2%	No change
Braidwell LP	596,900	$20.5M	0.8%	−250,251
Vanguard Capital Management LLC	488,805	$16.8M	0.0%	+15,273
Vestal Point Capital, LP	425,000	$14.6M	0.3%	+97,000
Kennedy Capital Management LLC	282,202	$9.7M	0.2%	−4,480
Geode Capital Management, LLC	270,461	$9.3M	0.0%	+2,188
Orbimed Advisors LLC	226,600	$7.8M	0.1%	No change
State Street Corp	219,908	$7.6M	0.0%	+6,403
Ikarian Capital, LLC	205,837	$7.1M	1.2%	+48,300
D. E. Shaw & Co., Inc.	186,550	$6.4M	0.0%	+70,430
Marshall Wace, Llp	172,101	$5.9M	0.0%	−57,494
Millennium Management LLC	165,525	$5.7M	0.0%	+107,177
Squarepoint Ops LLC	145,028	$5.0M	0.0%	−19,391
Ameriprise Financial Inc	142,448	$4.9M	0.0%	−984
Wells Fargo & Company/mn	117,428	$4.0M	0.0%	+4,764
Northern Trust Corp	113,904	$3.9M	0.0%	+35,551
Soleus Capital Management, L.P.	101,684	$3.5M	0.1%	−20,000
Woodline Partners LP	100,000	$3.4M	0.0%	No change
Vanguard Portfolio Management LLC	94,414	$3.2M	0.0%	+30,807

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARTectonic Therapeutic, Inc. filings on SEC EDGAR
2
SEC EDGARTectonic Therapeutic, Inc. filings on SEC EDGAR
3
SEC EDGARTectonic Therapeutic, Inc. 10-K for fiscal 2019
4
SEC EDGARTectonic Therapeutic, Inc. 10-K for fiscal 2020
5
SEC EDGARTectonic Therapeutic, Inc. 10-K for fiscal 2021
6
SEC EDGARTectonic Therapeutic, Inc. 10-K for fiscal 2022
7
SEC EDGARTectonic Therapeutic, Inc. 10-K for fiscal 2023
8
SEC EDGARTectonic Therapeutic, Inc. 10-K for fiscal 2024
9
SEC EDGARTectonic Therapeutic, Inc. 10-Q for fiscal 2026
10
SEC EDGARTectonic Therapeutic, Inc. 10-Q for fiscal 2026
11
SEC EDGARAlise Reicin, Chief executive officer
12
SEC EDGARErik Ostrowski, Chief executive officer
13
SEC EDGARGeoffrey Mackay, Chief executive officer
14
SEC EDGARBirgitte Volck, President
15
SEC EDGARDaniel Lochner, Chief financial officer
16
SEC EDGARErik Ostrowski, Chief financial officer
17
SEC EDGARKatina Dorton, Chief financial officer
18
SEC EDGARChristian Cortis, Chief operating officer
19
SEC EDGARMarc Schwabish, Chief Business Officer
20
SEC EDGARMarcella K. Ruddy, Chief Medical Officer
21
SEC EDGARPeter McNamara, Chief Scientific Officer
22
SEC EDGARAzadeh Golipour, Chief Technology Officer
23
SEC EDGARDiana Escolar, Chief Medical Officer
24
SEC EDGAREssra Ridha, Chief Medical Officer
25
SEC EDGARDeanna M. Petersen, Chief Business Officer
26
SEC EDGARGeoffrey Mackay, Officer
27
SEC EDGARNerissa Kreher, Chief Medical Officer
28
SEC EDGARFrancois Nader, Board member
29
SEC EDGARJessica Caroline Chutter, Board member
30
SEC EDGARPraveen P. Tipirneni, Board member
31
SEC EDGARStefan Vitorovic, Board member
32
SEC EDGARTerrance McGuire, Board member
33
SEC EDGARTimothy A. Springer, Board member
34
SEC EDGARGail M. Farfel, Board member
35
SEC EDGARPhilip J. Vickers, Board member
36
SEC EDGARAnnalisa Jenkins, Board member
37
SEC EDGARBruce Booth, Board member
38
SEC EDGARChristopher Paige, Board member
39
SEC EDGARIan T. Clark, Board member
40
SEC EDGARJoshua Resnick, Board member
41
SEC EDGARPhilip B. Donenberg, Board member
42
SEC EDGARScott Requadt, Board member
43
SEC EDGARSteven Avruch, General counsel